In humans, ipilimumab (α-CTLA-4) and nivolumab (α-PD-1) mAb combinational blockade has shown promise in clinical trials against advanced melanoma with 40-50% of patients achieving objective responses and a reduction in tumor burden [10]. Here, CTLA4 is linked to neoplasm.